Active not recruitingPHASE2INTERVENTIONAL

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

This research study is for people with advanced non-small cell lung cancer. It's testing different combinations of new medicines, including ones called Domvanalimab, Quemliclustat, and Zimberelimab, sometimes with existing treatments like Docetaxel. The main aim is to find out how effective these new combinations are at shrinking or controlling the cancer (this is called the 'objective response rate'). Researchers also want to understand how safe these new treatments are and what side effects they might cause. By looking at these things, the study hopes to discover better treatment options for this kind of cancer.

At a glance

Status

Active not recruiting

Phase

PHASE2

Sponsor

Gilead Sciences

Enrolment target

400

Start

21 Feb 2023

Estimated completion

01 Dec 2027

Advanced Non-Small Cell Lung Cancer

What is this study about?

This study is exploring potential new ways to treat a type of lung cancer called advanced non-small cell lung cancer. In this study, doctors are testing different combinations of new medications, often referred to as 'immunotherapy'. Immunotherapy works by helping your body's own immune system fight the cancer cells.

The study has a few main goals. Firstly, it wants to see how well these new combinations shrink the cancer or stop it from growing. This is important for understanding if the treatments are effective. Secondly, the researchers are carefully checking the safety of these new medicine combinations. They want to know what possible side effects might occur and how well people tolerate the treatments. This will help them understand if the treatments are not only effective but also manageable for patients.

By carefully studying these new combinations, the researchers hope to find more effective and safer treatment options for people living with advanced non-small cell lung cancer. This work is a step towards improving care and offering more choices for patients in the future.

Key takeaways

This study evaluates new immunotherapy combinations for advanced lung cancer.
It aims to find effective and safe new treatment options.
Participation involves regular medical check-ups and monitoring.
You might receive new treatments not yet widely available.
Your health and safety are a top priority throughout the study.

Who may be eligible?

To join this study, you would need to have advanced non-small cell lung cancer that has spread. Doctors would check that your general health is good enough for you to take part, and that the cancer can be measured. You would also need to be willing to provide a small sample of your tumour tissue for testing.

There are also some reasons why you might not be able to join. For example, if you have other serious health problems that the doctors think would make the study medicines unsafe for you. You also couldn't have had certain live vaccinations recently, or be taking high doses of steroid medications or other medicines that suppress your immune system just before starting the study. Certain autoimmune diseases might also prevent you from joining.

Quick self-check

Do you have advanced non-small cell lung cancer that has spread?
Is your general health good enough for you to take part?
Do you have cancer that doctors can measure?
Are you willing to provide a tumour tissue sample?
Have you avoided live vaccines in the last 28 days?
Are you taking any high-dose steroid or immune-suppressing medicines?

This is a guide only — the research team will confirm whether you can take part.

What does participation involve?

If you decide to take part in this study, you would receive one of the new medicine combinations. You would have regular visits to the clinic for check-ups, where doctors would monitor your health and how the treatment is affecting you. This would include tests like blood samples and scans to see how your cancer is responding. The doctors and nurses would also ask about any side effects you might be experiencing. The exact number of visits and tests, and the total length of time you'd be in the study, would be explained to you in detail.

Potential risks and benefits

Participating in this study might offer you access to new treatments before they are widely available. While there's no guarantee the treatment will work for you, it could potentially help control your cancer. However, all medicines have potential side effects, and some of the treatments in this study are new, so not all side effects might be fully known. Your health will be closely monitored, and you can withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (53)

University of Alabama at Birmingham (UAB)
Birmingham, United States
University of California San Diego (UCSD)
La Jolla, United States
Memorial Cancer Institute at Memorial Regional Hospital
Hollywood, United States
Hematology Oncology Associates Of The Treasure Coast
Port Saint Lucie, United States
Florida Cancer Specialists (Administration and Drug Shipment)
The Villages, United States
Northwestern Memorial Hospital
Chicago, United States
Ochsner Clinic Foundation
Jefferson, United States
Henry Ford Hospital
Detroit, United States
Virginia Cancer Specialists, PC
Fairfax, United States
Medical Oncology Associated, PS (dba Summit Cancer Centers)
Spokane, United States
The Border Cancer Hospital
Albury, Australia
Pindara Private Hospital
Benowa, Australia

+41 more sites — see the official record for the full list.

Common questions

What is non-small cell lung cancer?

It's the most common type of lung cancer, and 'advanced' means it has spread to other parts of the body.

What is immunotherapy?

Immunotherapy helps your body's own defence system fight cancer cells by boosting its ability to recognise and attack them.

What does a 'combination therapy' mean?

It means you'll be given more than one medicine at the same time, as they might work better together than alone.

Will I know which treatment I'm getting?

The study design details this. You will be fully informed before deciding to take part.

What happens after the study ends?

This will be discussed with you, but your care will always be continued by your regular medical team.